{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:21:59Z","timestamp":1761128519325,"version":"build-2065373602"},"reference-count":83,"publisher":"Elsevier BV","issue":"11-12","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.medmal.2006.07.020","type":"journal-article","created":{"date-parts":[[2006,11,21]],"date-time":"2006-11-21T12:16:31Z","timestamp":1164111391000},"page":"680-689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["13 \u2013 Antibiotic therapy of\u00a0community-acquired pneumonia (CAP) caused by\u00a0atypical agents"],"prefix":"10.1016","volume":"36","author":[{"given":"J.","family":"Roig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Casal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gispert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2006.07.020_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh519","article-title":"Anti-inflammatory effects of macrolides: an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?","volume":"55","author":"Amsden","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"issue":"7489","key":"10.1016\/j.medmal.2006.07.020_bib2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/bmj.38334.591586.82","article-title":"Effectiveness of \u00df-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community-acquired pneumonia: meta-analysis","volume":"330","author":"Mills","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.medmal.2006.07.020_bib3","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/archinte.165.17.1992","article-title":"Empirical atypical coverage for inpatients with community-acquired penumonia","volume":"165","author":"Shefet","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.medmal.2006.07.020_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/archinte.164.5.502","article-title":"Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia","volume":"164","author":"Roson","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.medmal.2006.07.020_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00001432-200304000-00011","article-title":"Legionella spp.: community-acquired and nosocomial infections","volume":"16","author":"Roig","year":"2003","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1183\/09031936.04.00135703","article-title":"Atypical pathogens and respiratory tract infections","volume":"24","author":"Blasi","year":"2004","journal-title":"Eur. Resp. J."},{"issue":"4","key":"10.1016\/j.medmal.2006.07.020_bib7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2000-9857","article-title":"Chlamydia pneumoniae pneumonia","volume":"21","author":"File","year":"2000","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.medmal.2006.07.020_bib8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0399-077X(03)00239-7","article-title":"Legionella pneumophila pneumonia: clinical and therapeutic aspects","volume":"33","author":"Chidiac","year":"2003","journal-title":"Med. Mal. Infect."},{"key":"10.1016\/j.medmal.2006.07.020_bib9","series-title":"Antimicrobial therapy and vaccines","first-page":"933","article-title":"Chlamydia pneumoniae","author":"Jackson","year":"2002"},{"key":"10.1016\/j.medmal.2006.07.020_bib10","series-title":"Antimicrobial therapy and vaccines","first-page":"949","article-title":"Mycoplasma pneumoniae","author":"McMillan","year":"2002"},{"key":"10.1016\/j.medmal.2006.07.020_bib11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-129-4-199808150-00012","article-title":"Antimicrobial chemotherapy for Legionnaires disease: time for a change","volume":"129","author":"Edelstein","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.medmal.2006.07.020_bib12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1046\/j.1445-5994.2003.00422.x","article-title":"Treatment and outcome of 104 hospitalized patients with Legionnaires\u2019 disease","volume":"33","author":"Howden","year":"2003","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.medmal.2006.07.020_bib13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(85)92164-6","article-title":"Efficacy of imipenem in experimental Legionnaires\u2019 disease","volume":"1","author":"Fitzgeorge","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2006.07.020_bib14","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1128\/aem.58.8.2420-2425.1992","article-title":"Relationship between Legionella pneumophila and Acanthamoeba polyphaga: physiological status and susceptibility to chemical inactivation","volume":"58","author":"Barker","year":"1992","journal-title":"Appl. Environ. Microbiol."},{"issue":"Suppl. D","key":"10.1016\/j.medmal.2006.07.020_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/22.Supplement_D.49","article-title":"Inhibition of Legionella pneumophila multiplication within human macrophages by fleroxacin","volume":"22","author":"Pohlod","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib16","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1128\/AAC.34.9.1733","article-title":"Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and oxoflacin against intracellular multiplication of Legionella pneumophila serogroup 1","volume":"34","author":"Rajagopalan-Levasseur","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib17","first-page":"849","article-title":"Antimicrobial therapy of experimentally induced Legionnaires\u2019 disease in guinea pigs","volume":"130","author":"Edelstein","year":"1984","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1164\/ajrccm.160.3.9901107","article-title":"Severe community-acquired pneumonia. Risk factors and follow-up epidemiology","volume":"160","author":"Ruiz","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.medmal.2006.07.020_bib19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkg191","article-title":"Legionnaires\u2019 disease: a rational approach to therapy","volume":"51","author":"Roig","year":"2003","journal-title":"JAC"},{"key":"10.1016\/j.medmal.2006.07.020_bib20","series-title":"Legionella: State of the Art 30 Years after its Recognition","article-title":"Treatment of Legionnaires\u2019 disease","author":"Roig","year":"2006"},{"key":"10.1016\/j.medmal.2006.07.020_bib21","series-title":"Legionella","first-page":"183","article-title":"Chemotherapy of Legionnaires\u2019 disease with macrolide or quinolone antimicrobial agents","author":"Edelstein","year":"2002"},{"key":"10.1016\/j.medmal.2006.07.020_bib22","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1378\/chest.128.3.1401","article-title":"Fluoroquinolones versus macrolides in the treatment of Legionnaires\u2019","volume":"128","author":"Sabri\u00e0","year":"2005","journal-title":"Dis. Chest"},{"key":"10.1016\/j.medmal.2006.07.020_bib23","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/428049","article-title":"Antimicrobial chemotherapy for Legionnaires\u2019 disease: levofloxacin versus macrolides","volume":"40","author":"Bl\u00e1zquez","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib24","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/428059","article-title":"Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy","volume":"40","author":"Mykietiuk","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1086\/431768","article-title":"Levofloxacin and macrolides for treatment of Legionnaires\u2019 disease. Multiple comparisons give few answers","volume":"41","author":"Kraus","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0272-5231(21)00109-X","article-title":"Legionnaires\u2019 disease. Infections caused by Legionella pneumophila and Legionella-like organisms","volume":"2","author":"Davis","year":"1981","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.medmal.2006.07.020_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-199346010-00005","article-title":"Treatment of Legionnaires\u2019 disease","volume":"46","author":"Roig","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2006.07.020_bib28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/00003495-200565050-00003","article-title":"Treatment of Legionnaires\u2019 disease","volume":"65","author":"Amsden","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2006.07.020_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.medmal.2004.10.010","article-title":"Legionnaires\u2019 disease: definition, diagnosis and treatment","volume":"35","author":"Benhamou","year":"2005","journal-title":"Med. Mal. Infect."},{"key":"10.1016\/j.medmal.2006.07.020_bib30","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1086\/374846","article-title":"Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?","volume":"36","author":"Sanchez","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib31","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1086\/379329","article-title":"Azithromycin in the treatment of Legionella pneumonia requiring hospitalization","volume":"37","author":"Plouffe","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/jac\/dki186","article-title":"Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes","volume":"56","author":"Baltch","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jac\/dki159","article-title":"Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in a vitro kinetic model","volume":"56","author":"Tano","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib34","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1128\/AAC.45.8.2204-2209.2001","article-title":"In vitro activity of gemifloxacin (SB-265805, LB2034a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia","volume":"45","author":"Edelstein","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dki391","article-title":"In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species","author":"Higa","year":"2005","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.medmal.2006.07.020_bib36","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1378\/chest.125.6.2135","article-title":"Levofloxacin efficacy in the treatment of community-acquired legionellosis","volume":"125","author":"Yu","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.medmal.2006.07.020_bib37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1179\/joc.2003.15.5.461","article-title":"Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases","volume":"15","author":"Santos","year":"2003","journal-title":"J. Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0163-4453(83)97034-2","article-title":"Antibiotic therapy of experimental airborne Legionnaires\u2019 disease","volume":"7","author":"Gibson","year":"1983","journal-title":"J. Infect."},{"key":"10.1016\/j.medmal.2006.07.020_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/23.1.37","article-title":"Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions","volume":"23","author":"Liebers","year":"1989","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/26.1.45","article-title":"The effects of single and combined antibiotics on the growth of Legionella pneumophila using time-kill studies","volume":"26","author":"Barker","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/jac\/22.4.457","article-title":"Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics","volume":"22","author":"Moffie","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0002-9343(84)90793-9","article-title":"Failure of erythromycin in treatment of Legionella micdadei pneumonia","volume":"76","author":"Rudin","year":"1984","journal-title":"Am. J. Med."},{"key":"10.1016\/j.medmal.2006.07.020_bib43","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijantimicag.2004.08.019","article-title":"Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing","volume":"25","author":"Stout","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.medmal.2006.07.020_bib44","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s10096-004-1152-2","article-title":"Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophilla","volume":"23","author":"Carbon","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib45","first-page":"503","article-title":"Efficacy and safety of pristinamycin versus amoxicillin in community acquired pneumonia in adults","volume":"53","author":"Tremolieres","year":"2005","journal-title":"Pathol. Biol. (Paris)"},{"key":"10.1016\/j.medmal.2006.07.020_bib46","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1128\/AAC.49.6.2533-2535.2005","article-title":"In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila","volume":"49","author":"Edelstein","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.medmal.2006.07.020_bib47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1185\/030079904125003304","article-title":"Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens","volume":"20","author":"Dunbar","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.medmal.2006.07.020_bib48","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1086\/429826","article-title":"Persistent culture-positive Legionella infection in an immunocompromised host","volume":"40","author":"Reilly","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib49","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00134-002-1304-8","article-title":"Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy","volume":"28","author":"Gacouin","year":"2002","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.medmal.2006.07.020_bib50","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1086\/498119","article-title":"Antibiotic prescription for community-acquired pneumonia in the Intensive Care Unit. Impact of adherence to IDSA guidelines and outcome","volume":"41","author":"Bodi","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib51","first-page":"327","article-title":"Severe community acquired Legionella pneumonia: treatment, complications and outcome","volume":"86","author":"Hubbard","year":"1993","journal-title":"Q. J. Med."},{"key":"10.1016\/j.medmal.2006.07.020_bib52","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1128\/AAC.40.6.1419","article-title":"In vitro synergy of macrolide-quinolone combinations against 41 clinical isolates of Legionella","volume":"40","author":"Martin","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib53","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/jac\/20.6.875","article-title":"Comparison of ciprofloxacin and rifampicin in experimental Legionella pneumophila pneumonia","volume":"20","author":"Havlichek","year":"1987","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib54","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1469-0691.2002.00392.x","article-title":"In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe","volume":"8","author":"Critchley","year":"2002","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.medmal.2006.07.020_bib55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568005054880109","article-title":"Mechanisms of drug resistance in Mycoplasma pneumoniae","volume":"5","author":"B\u00e9b\u00e9ar","year":"2005","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"10.1016\/j.medmal.2006.07.020_bib56","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1345\/aph.1E003","article-title":"Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections","volume":"38","author":"Yoo","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.medmal.2006.07.020_bib57","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1086\/430067","article-title":"Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections","volume":"40","author":"Lonks","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib58","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/CMR.17.4.697-728.2004","article-title":"Mycoplasma pneumoniae and its role as a human pathogen","volume":"17","author":"Waites","year":"2004","journal-title":"Clin. Microb. Rev."},{"key":"10.1016\/j.medmal.2006.07.020_bib59","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1128\/AAC.48.8.2897-2904.2004","article-title":"Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection","volume":"48","author":"Rios","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib60","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1128\/AAC.49.9.3970-3973.2005","article-title":"Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia","volume":"49","author":"Rios","year":"2005","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.medmal.2006.07.020_bib61","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1128\/AAC.49.10.4128-4136.2005","article-title":"Evaluation of LBM415(NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia","volume":"49","author":"Fonseca-Aten","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib62","series-title":"Emerging infections 5","first-page":"57","article-title":"Emerging from obscurity: understanding pulmonary and extrapulmonary syndromes, pathogenesis and epidemiology of human Mycoplasma pneumoniae infections","author":"Talkington","year":"2001"},{"key":"10.1016\/j.medmal.2006.07.020_bib63","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/thx.51.2.185","article-title":"Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia","volume":"51","author":"Kauppinen","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.medmal.2006.07.020_bib64","series-title":"Antimicrobial therapy and vaccines","first-page":"869","article-title":"Coxiella burnetii (Q fever)","author":"Marrie","year":"2002"},{"key":"10.1016\/j.medmal.2006.07.020_bib65","series-title":"Emerging infections 5","first-page":"29","article-title":"Fever: queries remaining after decades of research","author":"Raoult","year":"2001"},{"key":"10.1016\/j.medmal.2006.07.020_bib66","series-title":"Antimicrobial therapy and vaccines","first-page":"939","article-title":"Chlamydia psittaci (Psittacosis)","author":"Schlossberg","year":"2002"},{"key":"10.1016\/j.medmal.2006.07.020_bib67","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/ajcp\/87.5.669","article-title":"The pathology of fatal Mediterrenean spotted fever","volume":"87","author":"Walker","year":"1987","journal-title":"Am. J. Clin. Patol."},{"key":"10.1016\/j.medmal.2006.07.020_bib68","series-title":"Antimicrobial therapy and vaccines","first-page":"913","article-title":"Rickettsia species","author":"Raoult","year":"2002"},{"key":"10.1016\/j.medmal.2006.07.020_bib69","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijid.2004.09.011","article-title":"Clinical and laboratory features of murine typhus in central Tunisia: a report of 7 cases","volume":"9","author":"Letaief","year":"2005","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib70","series-title":"Antimicrobial therapy and vaccines","first-page":"301","article-title":"Francisella tularensis (Tularemia)","author":"Jacobs","year":"2002"},{"key":"10.1016\/j.medmal.2006.07.020_bib71","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00005792-198507000-00006","article-title":"Tularemia: a 30-year experience with 88 cases","volume":"64","author":"Evans","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.medmal.2006.07.020_bib72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF01964409","article-title":"In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularaemia with norfloxacin and ciprofloxacin","volume":"10","author":"Syrjala","year":"1991","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib73","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/clinids\/17.6.976","article-title":"Tularemia: treatment failures with outpatient use of ceftriaxone","volume":"17","author":"Cross","year":"1993","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.07.020_bib74","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7326\/0003-4819-101-1-92","article-title":"The neurotoxicity of antibacterial agents","volume":"101","author":"Snavely","year":"1984","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.medmal.2006.07.020_bib75","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00044011-200222060-00007","article-title":"Comparative tolerability of intravenous erythromycin and clarithromycin in hospitalised patients with community-acquired pneumonia. Results of a double-blind, randomised, prospective study","volume":"22","author":"Celis","year":"2002","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.medmal.2006.07.020_bib76","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/archderm.1996.03890320082013","article-title":"Serious adverse reactions induced by minocycline. Report of 13 patients and review of literature","volume":"132","author":"Knowles","year":"1996","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.medmal.2006.07.020_bib77","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.hrthm.2004.06.020","article-title":"Ciprofloxacin-induced acquired long QT syndrome","volume":"1","author":"Prabhakar","year":"2004","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.medmal.2006.07.020_bib78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tox.2005.04.002","article-title":"Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells","volume":"212","author":"Sendzik","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.medmal.2006.07.020_bib79","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1345\/aph.1E679","article-title":"Severe hyperglycemia during renally adjusted gatifloxacin therapy","volume":"39","author":"Blommel","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.medmal.2006.07.020_bib80","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00007890-198702000-00020","article-title":"Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin","volume":"43","author":"Jensen","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.medmal.2006.07.020_bib81","first-page":"291","article-title":"Traitement des l\u00e9gionelloses par ofloxacine chez le transplant\u00e9 r\u00e9nal. Absence d'interf\u00e9rence avec la ciclosporine A","volume":"20","author":"Wynckel","year":"1991","journal-title":"Presse Med."},{"key":"10.1016\/j.medmal.2006.07.020_bib82","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/jac\/22.6.952","article-title":"Ciprofloxacin: a preferred treatment for Legionella infections in patients receiving cyclosporin A","volume":"22","author":"Hooper","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.medmal.2006.07.020_bib83","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/clinids\/14.1.272","article-title":"Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management","volume":"14","author":"Radandt","year":"1992","journal-title":"Clin. Infect. Dis."}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X0600237X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X0600237X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:05:59Z","timestamp":1759971959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X0600237X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":83,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0399077X0600237X"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2006.07.020","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"13 \u2013 Antibiotic therapy of\u00a0community-acquired pneumonia (CAP) caused by\u00a0atypical agents","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2006.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}